Case Comprehensive Cancer Center — Biomedical Watch V2

Traitements4programmes

Essais2liés

Publications2liées

SourceDBlocale

Traitements

4

Molécule	Indication / population	Phase	Objectif	Pays	Résultat
ChemotherapyThis phase III trial compares standard of care hormone therapy plus ribociclib to chemotherapy followed by hormone therapy plus ribociclib for the treatment of patients with high anatomic stage breast cancer with low risk of the cancer returning (low risk recurrence). Ribociclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Hormone therapy, with letrozole, anastrozole or exemestane, lowers the amount of estrogen made by the body. This may help stop the growth of tumor cells that need estrogen to grow. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Hormone therapy plus ribociclib may work as well as chemotherapy followed by hormone therapy plus ribociclib for the treatment of high anatomic stage breast cancer with low recurrence risk.	Cancer	Non applicable	Ablation tumorale non thermique	United States	Dispositif/procédure : résultats à interpréter par essai et indication.
High-intensity focused ultrasound (HIFU)This study aims to compare the novel single-port robotic partial prostatectomy to High-intensity focused ultrasound (HIFU) in patients with low to intermediate risk localized prostate cancer. These interventions have become acceptable focal therapies prevalent with beneficial oncologic outcomes and therefore need to be examined further.	Cancer	Non applicable	À vérifier	United States	À vérifier
Transvesical Single Port Robotic Partial ProstatectomyThis study aims to compare the novel single-port robotic partial prostatectomy to High-intensity focused ultrasound (HIFU) in patients with low to intermediate risk localized prostate cancer. These interventions have become acceptable focal therapies prevalent with beneficial oncologic outcomes and therefore need to be examined further.	Cancer	Non applicable	À vérifier	United States	À vérifier
Transvesical Single Port Robotic Partial ProstatectomyThis study aims to compare the novel single-port robotic partial prostatectomy to High-intensity focused ultrasound (HIFU) in patients with low to intermediate risk localized prostate cancer. These interventions have become acceptable focal therapies prevalent with beneficial oncologic outcomes and therefore need to be examined further.	Cancer	Non applicable	À vérifier	United States	À vérifier

Essais cliniques

2

Molécule	Indication / population	Phase	NCT	Titre	Statut
Transvesical Single Port Robotic Partial Prostatectomy	Cancer	Non applicable	NCT05610852	Single-Port Transvesical Partial Prostatectomy Versus High Intensity Focused Ultrasound	RECRUITING
Histotripsie — HistoSonics Edison System	Cancer	Non applicable	NCT07044362	Histotripsy Plus Chemotherapy vs Chemotherapy Alone for Advanced Colorectal Liver Metastasis	RECRUITING

Publications

2

Molécule	Indication / population	Titre	Journal	Date
Transvesical Single Port Robotic Partial Prostatectomy		A Narrative Review of da Vinci Single-Port Versus Multi-Port Robotic Surgery in Elderly or Frail Urological Cancer Patients.	Cancers
Chemotherapy		Transpapillary Placement of a Multihole Covered Metal Stent Using a 5.9-Fr Delivery System Through a Forward-viewing Endoscope in Malignant Biliary Obstruction With Type I Duodenal Stenosis.	DEN open